Experimental Design: Part A of the study followed a multiple-ascending dose design to establish the maximum tolerated dose (MTD) of saracatinib. Part B was a randomized, parallel-group, cohort-expansion phase to further assess tolerated doses. Safety, tolerability and Src activity (immunohistochemistry and lysatebased methodologies) were assessed after 21 days' once-daily oral dosing. PK was assessed after single and multiple dosing. Conclusions: Saracatinib was well tolerated in patients with advanced solid malignancies. A reduction in tumor Src activity was observed. PK data demonstrate that saracatinib is suitable for once-daily oral dosing. Based on this
Introduction
Src is a ubiquitously expressed, but highly regulated, non-receptor tyrosine kinase that acts as a signal integration point in diverse cellular signaling pathways (1) . Dysregulation of Src has been implicated in numerous tumor types, and is thought to mediate processes important for tumor progression, such as cellular adhesion, migration, survival and proliferation (2) . Targeted inhibition of Src signaling in tumors is an attractive strategy for cancer therapy (3, 4) . 
Saracatinib (AZD0530) is an orally available Src inhibitor that has shown
anticancer effects in preclinical models (9, 10) . A study in healthy volunteers has shown that saracatinib is generally well tolerated at doses up to and including 250 mg once daily, with the most frequently reported adverse events (AEs) being mild maculo-papular facial/thoracic rash and diarrhea (11).
Research. Here we report the first study of saracatinib monotherapy in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic (PK) profile of saracatinib.
Patients and Methods
Study design. This was a two-part, phase I, open-label, multicenter study of once-daily oral saracatinib in patients with advanced solid malignancies. The primary objective was to evaluate the safety and tolerability of saracatinib, and secondary objectives included evaluation of PK, Src-mediated activity inhibition and antitumor activity.
Part A was a classic 3 + 3 patient dose-escalation study to identify the maximum tolerated dose (MTD) of saracatinib. The starting dose was 60 mg (selected based on review of available preclinical and clinical data) with dose doubling escalations until ≥2 patients experienced a dose-limiting toxicity (DLT).
A DLT was initially defined as any grade ≥3 toxicity despite adequate treatment considered by the investigator to be possibly related to saracatinib treatment. As the study progressed, the DLT definition was refined to the following: (i) hematologic: febrile neutropenia (grade 3 with temperature ≥38.5ºC, or grade 4 with temperature ≥38ºC); anemia (increase of 3 or more grades over the grade at study entry, despite appropriate treatment); any grade 4 hematologic toxicity; (ii) non-hematologic: asthenia (increase of 3 or more grades over the grade at study entry, despite appropriate treatment); any other toxicity of grade ≥3 which in the opinion of the investigator was related to study drug, except sub-optimally treated nausea, vomiting or diarrhea. Thereafter, dose escalation was to be by single
Research. Patient exclusion criteria included inadequate bone marrow reserve; radiotherapy or chemotherapy within the 4 weeks prior to the first dose of saracatinib (6 weeks for nitrosoureas, mitomycin C or suramin); active or symptomatic brain metastases; or history of ischemic heart disease, myocardial infarction or unstable cardiac disease within 3 months of study entry. In Part A, there was a requirement that the primary tumor should be Src positive at screening biopsy.
This was confirmed by immunohistochemistry (IHC) using a Clone 28 monoclonal antibody which recognises an epitope adjacent to the regulatory Cterminal tyrosine (Tyr-530) and binds to activated Src that is dephosphorylated at this site (12) . However, this requirement was omitted from Part B because almost all patients screened in Part A had Src-positive tumors.
Research. concentrations were also determined in homogenized tumor core biopsy samples.
Additional details of the PK assessments and assay methods are described in the online Appendix.
Assessment of Src activity in tumor biopsies. Biopsy samples from one tumor lesion per patient were obtained prior to and after 21 daily doses of saracatinib. A maximum of four core biopsies were taken using the standard biopsy techniques used at each investigational site. Biopsy samples collected for Luminex assay were frozen within 5 minutes after removal whilst those collected for IHC analysis were formalin fixed and stored at room temperature prior to paraffin embedding.
The presence of FAK, p-FAK, PAX and p-PAX in tumor biopsy samples was assessed quantitatively by Luminex assay and semi-quantitively by IHC analysis of formalin-fixed and paraffin-embedded tissue following antigen retrieval using an antibody against a particular tyrosine residue phosphorylated by Src (pY861 on FAK and pY31 on PAX) as described previously (6) . For Luminex assessment the p-PAX:total PAX ratio was predefined as the primary measure of Src activity based on a pilot study (8) . IHC samples were assessed using H-score based on intensity and location of staining by review of samples by a blinded pathology
Research.
on July Table 1 . Of the 81 patients, 58 (72%) received saracatinib for ≥28 days, 17 (21%) for ≥8 weeks, and 13 (16%) for ≥12 weeks.
The maximum duration of therapy was 210 days (saracatinib 125 mg).
Tolerability, toxicity, and maximum tolerated dose. DLTs occurred in three of seven patients in the 250 mg group (grade 3 leucopenia, grade 3 renal failure and grade 5 septic shock, and grade 3 asthenia) and two patients of seven in the subsequent 200 mg group (grade 3 febrile neutropenia and grade 5 respiratory failure), indicating that these were non-tolerated doses (Table 2) .
Saracatinib 175 mg once daily was identified as the MTD and doses of 50 mg, 125 mg and 175 mg were evaluated in Part B.
Safety data from Parts A and B were combined to evaluate the tolerability profile of saracatinib. The majority of AEs (regardless of causality) were mild or moderate (grade 1 or 2); only 11% were grade ≥3. A total of 51/81 (63%) patients experienced AEs that were considered by the investigator to be treatment related (Table 3 ). Overall, 6/81 (7%) patients experienced dose interruptions or reductions; five due to clinically relevant AEs, and one had a dose reduction because the dose had been declared intolerable by the Safety Review
Committee.
Serious AEs occurred in 23 (28%) patients and were considered by the investigator to be related to study treatment in 9 (11%) patients. Thirteen patients
on Fig. 1 ).
Both C max and AUC 0-24 were higher at steady state than after a single dose. Tumor biopsy specimens for determination of concentrations of saracatinib and M594347 were available from 20 patients after 21 saracatinib daily doses.
The concentrations of saracatinib were much greater in tumor biopsies than in plasma. In view of the accumulation of saracatinib in the body and the high apparent tumor penetration it was considered that at steady state the levels in
Research. patients (41%) were evaluable. Reductions from baseline in p-PAX:total PAX ratio were observed in 2/8 samples from those who received saracatinib 50 mg, 3/6 who received 125 mg, and 6/7 who received 175 mg (Fig. 1D) . Moreover, 4/7 patients who received saracatinib 175 mg exhibited a pre-defined ≥50% reduction in p-PAX:total PAX ratio.
Antitumor activity. Eleven of 81 patients had confirmed stable disease (confirmed 6 weeks after initial assessment) and 11 had unconfirmed stable disease. There were no complete responses or confirmed partial responses.
on 
Discussion
In this phase I study, patients with advanced solid tumors treated with saracatinib experienced a manageable safety and tolerability profile. Saracatinib was shown to be well tolerated at doses up to 175 mg once daily, which was determined to be the MTD as monotherapy.
Src inhibition, as an anticancer strategy, was initially demonstrated in patients with leukemia who received the Src/Abl inhibitor dasatinib (13) . In contrast to dasatinib, saracatinib has a >10-fold preference for Src over Abl kinases (9) . This distinct and predominantly Src-targeted inhibition profile might be expected to produce clinical effects distinct from those of Src/Abl inhibitors, both in terms of efficacy and tolerability. Fluid retention and myelosuppression have previously been reported in dasatinib and bosutinib trials (14-16). However, a low incidence of fluid retention was observed in the present study and the reductions in neutrophil count were moderate and generally resolved without the need for dose interruption or additional supportive care. The selection criteria for this study allowed patients with grade 2 hematological derangements to be enrolled, such that a proportion of patients had anemia or low neutrophil counts at study entry. Although hematological AEs were generally moderate, two of the observed DLTs were hematological. Mild non-clinically-relevant increases in serum creatinine were observed during saracatinib treatment however, a study in healthy volunteers has determined the creatinine increase to be due to a reduction in renal tubular secretion of creatinine (17).
on DLT, dose-limiting toxicity.
*The Investigator felt that renal failure was causally related to a study procedure (administration of intravenous radiological contrast medium and dehydration) and was not causally related to saracatinib treatment. AstraZeneca felt that a relationship to saracatinib treatment could not be excluded. †
In the opinion of the Investigator, the death due to septic shock was considered related to disease progression, but the event was considered by the Safety Review Committee to be a dose limiting toxicity as a relationship to saracatinib treatment could not be totally excluded.
Research. Abbreviations: C max , maximal plasma concentration; C min , minimal plasma concentration; AUC 0-24 , area under the plasma concentration-time curve from 0 to 24 hours, t max , time to maximal plasma concentration; CL/F, apparent oral clearance; t ½ , half-life; Rac, accumulation ratio (AUC 0-24 at steady state divided by AUC 0-24 single dose); V ss /F, apparent steady-state volume of distribution. *Unless specified otherwise. Geometric mean (coefficient of variation) except: † median (range); ‡ arithmetic mean (standard deviation). 
